Newsroom

Press Release

NeoGenomics Announces Pricing of $9.5 Million Public Offering

NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012

NeoGenomics Schedules its Q4 and Full Year 2012 Earnings Release for February 14, 2013

NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer

NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients